| 摘要 |
The compositions and compounds of formula I which includes a salt of ranolazine or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of angina, angina pectoris, diabetes, hyperglycemia, elevated glucose levels, deep venous thrombosis, prevention of secondary venous thromboembolism and complications of atrial fibrillation such as stroke and additional risk factor for stroke. |
